ECSP13013072A - Derivados de pirazol - Google Patents

Derivados de pirazol

Info

Publication number
ECSP13013072A
ECSP13013072A ECSP13013072A ECSP13013072A EC SP13013072 A ECSP13013072 A EC SP13013072A EC SP13013072 A ECSP13013072 A EC SP13013072A EC SP13013072 A ECSP13013072 A EC SP13013072A
Authority
EC
Ecuador
Prior art keywords
halogen
disorders
lower alkyl
optionally substituted
substituted
Prior art date
Application number
Other languages
English (en)
Inventor
Roger David Norcross
Guido Galley
Philippe Pflieger
Cédric Ghellamallah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46298390&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13013072(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP13013072A publication Critical patent/ECSP13013072A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a compuestos de la fórmula IA o IBen las que:R1 es hidrógeno o fenilo opcionalmente sustituido por haló-geno, CN o alcoxi inferior o alcoxi inferior sustituido por halógeno; R2 es hidrógeno o alquilo inferior;R3 es hidrógeno o alquilo inferior o es fenilo opcionalmente sustituido por uno o más sustituyentes elegidos entre halógeno, ciano o alcoxi inferior sustituido por halógeno, o es piridinilo opcionalmente sustituido por halógeno o alquilo inferior sustituido por halógeno, o es pirimidinilo, opcionalmente sustituido por alquilo inferior sustituido por halógeno, o es pirazinilo, opcionalmente sustituido por halógeno, ciano o alquilo inferior sustituido por halógeno;R4 es hidrógeno, alquilo inferior o fenilo;Z es un enlace, -CH2- u -O-;o a una sal de adición de ácido farmacéuticamente aceptable de los mismos.Ahora se ha encontrado que los compuestos de las fórmulas IA e IB tienen buena afinidad con los receptores asociados con las aminas traza (TAARs), en especial con el TAAR1.Estos compuestos pueden utilizarse para el tratamiento de la depresión, los trastornos de ansiedad, el trastorno bipolar, el trastorno de hiperactividad con déficit de atención (ADHD), los trastornos relacionados con el estrés, los trastornos psicóticos como son la esquizofrenia, las enfermedades neurológicas, por ejemplo la enfermedad de Parkinson, los trastornos neurodegenerativos, por ejemplo la enfermedad de Alzheimer, la epilepsia, la migraña, la hipertensión, el abuso de sustancias y los trastornos metabólicos, por ejemplo los trastornos de ingestión de comida, la diabetes, las complicaciones diabéticas, la obesidad, la dislipidemia, los trastornos de consumo y asimilación de energía, los trastornos y malfunción de la temperatura corporal, la homeostasis, los trastornos del sueño y del ritmo circadiano y los trastornos cardiovasculares.
ECSP13013072 2011-06-09 2013-12-09 Derivados de pirazol ECSP13013072A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11169217 2011-06-09

Publications (1)

Publication Number Publication Date
ECSP13013072A true ECSP13013072A (es) 2014-01-31

Family

ID=46298390

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13013072 ECSP13013072A (es) 2011-06-09 2013-12-09 Derivados de pirazol

Country Status (32)

Country Link
US (1) US9073911B2 (es)
EP (1) EP2717873B1 (es)
JP (1) JP5914642B2 (es)
KR (1) KR101574905B1 (es)
CN (1) CN103596567B (es)
AR (1) AR088741A1 (es)
AU (1) AU2012266457B2 (es)
BR (1) BR112013031324B1 (es)
CA (1) CA2837255C (es)
CL (1) CL2013003484A1 (es)
CO (1) CO6801764A2 (es)
CY (1) CY1116778T1 (es)
DK (1) DK2717873T3 (es)
EA (1) EA024648B1 (es)
EC (1) ECSP13013072A (es)
ES (1) ES2546438T3 (es)
HR (1) HRP20151077T1 (es)
IL (1) IL229549B (es)
MA (1) MA35192B1 (es)
MX (1) MX347239B (es)
MY (1) MY162160A (es)
PE (1) PE20140934A1 (es)
PH (1) PH12013502315A1 (es)
PL (1) PL2717873T3 (es)
PT (1) PT2717873E (es)
RS (1) RS54183B1 (es)
SG (1) SG195156A1 (es)
SI (1) SI2717873T1 (es)
TW (1) TWI440636B (es)
UA (1) UA110525C2 (es)
WO (1) WO2012168260A1 (es)
ZA (1) ZA201308939B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029370B2 (en) * 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
BR112014015832A8 (pt) 2012-01-12 2017-07-04 Hoffmann La Roche derivados heterocíclicos como receptores associados com aminas vistigiais (taars)
HRP20171981T1 (hr) 2012-09-14 2018-02-09 F. Hoffmann - La Roche Ag Derivati pirazolkarboksamida kao taar modulatora za uporabu u liječenju nekoliko poremećaja poput depresije, dijabetesa i parkinsonove bolesti
EP2928473B1 (en) * 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
WO2015165085A1 (en) * 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
RS60825B1 (sr) * 2016-03-17 2020-10-30 Hoffmann La Roche Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a
WO2018200517A1 (en) 2017-04-24 2018-11-01 Tesaro, Inc. Methods of manufacturing of niraparib
CN112457255B (zh) * 2017-11-08 2022-08-19 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途
EA202190055A1 (ru) * 2018-06-18 2021-04-23 Янссен Фармацевтика Нв Производные пиразола в качестве ингибиторов malt1
KR102161787B1 (ko) * 2018-07-02 2020-10-06 한국기초과학지원연구원 수면 장애의 예방 또는 치료용 약학적 조성물
CN112752755A (zh) 2018-09-27 2021-05-04 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的杂环基化合物
KR102396602B1 (ko) * 2019-02-28 2022-05-11 주식회사 마더스제약 피라졸 아마이드 유도체 화합물 및 이의 용도
EP3983386A4 (en) * 2019-05-14 2023-01-11 Metabomed Ltd ACSS2 INHIBITORS AND METHODS OF USE THEREOF
CN114144412A (zh) * 2019-07-11 2022-03-04 豪夫迈·罗氏有限公司 用于制备经取代的吡唑衍生物的方法
US20240400577A1 (en) * 2021-07-08 2024-12-05 Vibliome Therapeutics, Llc Modulators of protein kinases
WO2023183444A1 (en) * 2022-03-24 2023-09-28 Vibliome Therapeutics, Llc Modulators of protein kinases
CN119654138A (zh) * 2022-08-12 2025-03-18 豪夫迈·罗氏有限公司 包含5-乙基-4-甲基-n-[4-[(2s)吗啉-2-基]苯基]-1h-吡唑-3-甲酰胺的药物组合物
KR20250176791A (ko) 2024-06-13 2025-12-22 인천대학교 산학협력단 피라졸 유도체를 유효성분으로 포함하는 항노화 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
PT1036065E (pt) 1997-12-04 2004-09-30 Allergan Inc Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US9132136B2 (en) * 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
US9029370B2 (en) * 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
CN102899314A (zh) 2011-07-29 2013-01-30 江汉大学 一种批量基因克隆的方法

Also Published As

Publication number Publication date
MA35192B1 (fr) 2014-06-02
HK1191862A1 (zh) 2014-08-08
BR112013031324A2 (pt) 2016-11-29
CA2837255A1 (en) 2012-12-13
TW201302727A (zh) 2013-01-16
DK2717873T3 (en) 2015-07-27
JP5914642B2 (ja) 2016-05-11
JP2014516066A (ja) 2014-07-07
HRP20151077T1 (hr) 2015-11-06
BR112013031324B1 (pt) 2021-11-03
IL229549B (en) 2019-06-30
AU2012266457B2 (en) 2016-09-08
KR101574905B1 (ko) 2015-12-04
TWI440636B (zh) 2014-06-11
ES2546438T3 (es) 2015-09-23
ZA201308939B (en) 2014-08-27
MX347239B (es) 2017-04-20
AU2012266457A1 (en) 2013-11-14
EP2717873B1 (en) 2015-07-15
MY162160A (en) 2017-05-31
RS54183B1 (sr) 2015-12-31
NZ617350A (en) 2016-01-29
KR20140029517A (ko) 2014-03-10
CA2837255C (en) 2020-10-27
AR088741A1 (es) 2014-07-02
PT2717873E (pt) 2015-09-18
PH12013502315A1 (en) 2016-05-11
WO2012168260A1 (en) 2012-12-13
US20120316172A1 (en) 2012-12-13
UA110525C2 (ru) 2016-01-12
CY1116778T1 (el) 2017-03-15
US9073911B2 (en) 2015-07-07
MX2013013853A (es) 2014-01-20
SI2717873T1 (sl) 2015-09-30
SG195156A1 (en) 2013-12-30
PL2717873T3 (pl) 2015-12-31
CN103596567B (zh) 2016-03-16
EA201391787A1 (ru) 2014-04-30
IL229549A0 (en) 2014-01-30
CO6801764A2 (es) 2013-11-29
EA024648B1 (ru) 2016-10-31
PE20140934A1 (es) 2014-08-06
CL2013003484A1 (es) 2014-08-08
EP2717873A1 (en) 2014-04-16
CN103596567A (zh) 2014-02-19

Similar Documents

Publication Publication Date Title
AR088741A1 (es) Derivados de pirazol
MX351918B (es) Derivados heterociclicos de amina.
AR092537A1 (es) Derivados de pirazol-carboxamida
AR089691A1 (es) Derivados heterociclicos
ECSP12012098A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos
MY176030A (en) Substituted benzamide derivatives
AR067772A1 (es) Derivados piperazinicos de nicotinamida, medicamentos que los contienen, proceso para prepararlos y usos de los mismos para el tratamiento de trastornos asociados al sistema nervioso, cardiovascular y/o trastornos metabolicos.
MX361761B (es) Derivados de triazol carboxamida.
MX354410B (es) Derivados de benzamida sustituida.
ECSP11010782A (es) Derivados de 4,5-dihidro-oxazol-2-ilo
MX2017001096A (es) Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo.
MX2016016488A (es) Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar).
MX377195B (es) Derivados de morfolina-piridina.
MX349738B (es) Derivados de dihidrooxazol-2-amina.
AR093372A1 (es) Derivados de pirazina
AR076979A1 (es) 2- aminooxazolinas como ligandos de taar1
AR063811A1 (es) 4-imidazoles sustituidos
AR067675A1 (es) 2-azetidinametanoaminas y 2-pirrolidinametanoaminas como ligandos de taar, un metodo para su preparacion y su uso en la fabricacion de un medicamento para el tratamiento de trastornos del snc.
MX2016016190A (es) Derivados de pirazino[2,1-a]isoquinolina sustituida para el tratamiento de trastornos del sistema nervioso central.